Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for Korro Bio (KRRO) over the last 5 years, with Q3 2025 value amounting to $1.5 million.

  • Korro Bio's Other Non-Current Liabilities rose 11366.81% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 11366.81%. This contributed to the annual value of $1.5 million for FY2024, which is 3979.11% up from last year.
  • According to the latest figures from Q3 2025, Korro Bio's Other Non-Current Liabilities is $1.5 million, which was up 11366.81% from $1.4 million recorded in Q2 2025.
  • Korro Bio's 5-year Other Non-Current Liabilities high stood at $1.5 million for Q3 2025, and its period low was $57000.0 during Q1 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $805000.0 (2024), whereas its average is $763642.9.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 8256.41% in 2022, then surged by 11366.81% in 2025.
  • Korro Bio's Other Non-Current Liabilities (Quarter) stood at $87000.0 in 2021, then dropped by 9.2% to $79000.0 in 2022, then soared by 1232.91% to $1.1 million in 2023, then skyrocketed by 39.79% to $1.5 million in 2024, then increased by 4.08% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.4 million for Q2 2025, and $1.4 million during Q1 2025.